Published in J Natl Cancer Inst on November 17, 2009
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (2013) 9.01
The missing voice of patients in drug-safety reporting. N Engl J Med (2010) 4.23
Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol (2011) 3.62
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst (2011) 2.56
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol (2015) 2.19
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol (2015) 2.09
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst (2014) 2.01
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol (2011) 1.75
Reliability of adverse symptom event reporting by clinicians. Qual Life Res (2011) 1.45
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. J Clin Oncol (2013) 1.34
Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res (2013) 1.33
Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res (2011) 1.23
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res (2013) 1.21
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer (2013) 1.21
Improving modern cancer care through information technology. Am J Prev Med (2011) 1.19
Review of electronic patient-reported outcomes systems used in cancer clinical care. J Oncol Pract (2013) 1.15
Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood (2013) 1.14
Electronic toxicity monitoring and patient-reported outcomes. Cancer J (2011) 1.06
A framework for understanding cancer comparative effectiveness research data needs. J Clin Epidemiol (2012) 1.00
Cancer-related and treatment-related fatigue. Gynecol Oncol (2014) 0.98
Integrating Patient-Reported Outcome Measures into Routine Cancer Care: Cancer Patients' and Clinicians' Perceptions of Acceptability and Value. EGEMS (Wash DC) (2015) 0.97
The role of informatics in promoting patient-centered care. Cancer J (2011) 0.96
Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol (2016) 0.94
Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clin Trials (2015) 0.93
The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer (2016) 0.92
Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer (2010) 0.90
Patient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer. Gastrointest Cancer Res (2012) 0.89
Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol (2013) 0.89
Health information technology in oncology practice: a literature review. Cancer Inform (2014) 0.88
The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer (2011) 0.87
Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence (2015) 0.87
Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat (2013) 0.86
Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy. PLoS One (2013) 0.85
Concordance between patient reports of cancer-related symptoms and medical records documentation. J Pain Symptom Manage (2012) 0.85
Patient symptoms and clinician toxicity ratings: both have a role in cancer care. J Natl Cancer Inst (2009) 0.84
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol (2015) 0.83
Adverse events following trigger point dry needling: a prospective survey of chartered physiotherapists. J Man Manip Ther (2014) 0.83
Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther (2016) 0.83
Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica (2013) 0.82
Health-related quality of life following allogeneic hematopoietic stem cell transplantation. Hematology Am Soc Hematol Educ Program (2010) 0.81
Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study. Health Qual Life Outcomes (2014) 0.81
Improving symptom communication through personal digital assistants: the CHAT (Communicating Health Assisted by Technology) project. J Natl Cancer Inst Monogr (2013) 0.81
Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development. World J Gastroenterol (2013) 0.81
Defining a Research Agenda for Patient-Reported Outcomes in Surgery: Using a Delphi Survey of Stakeholders. JAMA Surg (2016) 0.81
PERSYVE - Design and validation of a questionnaire about adverse effects of antihypertensive drugs. Pharm Pract (Granada) (2014) 0.79
Oncologists' assessments of lung cancer patient and family disagreements regarding treatment decision making. Lung Cancer (2012) 0.79
Concept-elicitation phase for the development of the pediatric patient-reported outcome version of the Common Terminology Criteria for Adverse Events. Cancer (2015) 0.77
Determining adverse events in patients with neck pain receiving orthopaedic manual physiotherapy: a pilot and feasibility study. Physiother Can (2013) 0.77
Structured decision-making: using personalized medicine to improve the value of cancer care. J Pers Med (2012) 0.77
The use of capecitabine in daily practice: a study on adherence and patients' experiences. Patient Prefer Adherence (2012) 0.77
Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications. Support Care Cancer (2016) 0.76
Patient-Reported Safety Events in Chronic Kidney Disease Recorded With an Interactive Voice-Inquiry Dial-Response System: Monthly Report Analysis. J Med Internet Res (2016) 0.76
Assessment of Cancer-Related Fatigue, Pain, and Quality of Life in Cancer Patients at Palliative Care Team Referral: A Multicenter Observational Study (JORTC PAL-09). PLoS One (2015) 0.76
Development and preliminary evaluation of a training workshop for the collection of patient-reported outcome (PRO) interview data by research support staff. J Cancer Educ (2013) 0.76
Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. Front Pharmacol (2016) 0.75
Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. Int J Radiat Oncol Biol Phys (2016) 0.75
Cognitive Interview-based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Adolescents with Cancer. J Pain Symptom Manage (2017) 0.75
Telemedicine to Promote Patient Safety: Use of Phone-Based Interactive Voice-Response System to Reduce Adverse Safety Events in Pre-dialysis CKD. Adv Chronic Kidney Dis (2017) 0.75
A Novel Digital Patient-Reported Outcome Platform for Head and Neck Oncology Patients-A Pilot Study. Clin Med Insights Ear Nose Throat (2016) 0.75
Evaluation of electronic patient-reported outcome assessment with cancer patients in the hospital and at home. BMC Med Inform Decis Mak (2015) 0.75
Promoting patient participation in healthcare interactions through communication skills training: A systematic review. Patient Educ Couns (2017) 0.75
Manifesto: towards a clinically-oriented psychometrics. Health Qual Life Outcomes (2017) 0.75
Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Res Clin Oncol (2017) 0.75
The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review. Support Care Cancer (2015) 0.75
Patient-reported problems after office procedures. JAMA Intern Med (2013) 0.75
Systematic collection of patient reported outcome research data: A checklist for clinical research professionals. Contemp Clin Trials (2016) 0.75
Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms Assessed During Clinical Medication Reviews: A Cross-Sectional Observational Study. Drug Saf (2017) 0.75
To Improve Cancer Treatment, We Need to Have Patients and Care Teams Connected! Cancer Nurs (2017) 0.75
Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT. Adv Ther (2016) 0.75
Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Oncologist (2017) 0.75
Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial. Breast Cancer Res Treat (2015) 0.75
Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. J Med Internet Res (2017) 0.75
Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. Nat Rev Clin Oncol (2017) 0.75
Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting. Support Care Cancer (2016) 0.75
Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy. Support Care Cancer (2017) 0.75
Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. Support Care Cancer (2016) 0.75
Evaluation of a weekly speech pathology/dietetic service model for providing supportive care intervention to head and neck cancer patients and their carers during (chemo)radiotherapy. Support Care Cancer (2015) 0.75
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
EQ-5D: a measure of health status from the EuroQol Group. Ann Med (2001) 18.69
When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain (1995) 5.97
Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol (2004) 5.84
Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA (2002) 5.30
Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res (1993) 5.01
Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer (1980) 4.31
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol (2005) 3.29
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol (2004) 3.16
The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol (2008) 3.14
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol (2004) 2.92
Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res (2004) 2.80
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol (2007) 1.84
Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer (1991) 1.69
Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.67
The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol (2000) 1.53
Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain (2006) 1.48
Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol (2000) 1.44
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med (2007) 1.34
Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer (2006) 1.31
Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst (1993) 1.22
Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials? J Clin Oncol (2007) 1.12
The regulation of patient-reported outcome claims: need for a flexible standard. Value Health (2002) 1.10
Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys (2008) 1.10
Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol (2004) 1.09
Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making. J Clin Oncol (2007) 1.06
Patient-reported outcomes supporting anticancer product approvals. J Clin Oncol (2007) 1.03
Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. J Oncol Manag (2002) 0.99
Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions. J Clin Oncol (2007) 0.98
Mild, moderate, or severe pain categorized by patients with cancer with bone metastases. J Palliat Med (2006) 0.92
FDA turns to electronic "sentinel" to flag prescription drug safety problems. JAMA (2008) 0.90
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Primary care physicians who treat blacks and whites. N Engl J Med (2004) 12.23
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
Care patterns in Medicare and their implications for pay for performance. N Engl J Med (2007) 6.74
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69
Using navigators to improve care of underserved patients: current practices and approaches. Cancer (2005) 5.56
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA (2004) 5.43
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol (2006) 4.97
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol (2007) 4.81
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol (2004) 4.77
Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist (2013) 4.33
Survival of blacks and whites after a cancer diagnosis. JAMA (2002) 4.27
How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA (2009) 4.04
The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med (2003) 4.01
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol (2006) 3.83
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res (2007) 3.74
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol (2012) 3.63
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60
Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med (2009) 3.59
Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care (2002) 3.57
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol (2014) 3.57
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res (2011) 3.56
Delivery of preventive services to older adults by primary care physicians. JAMA (2005) 3.53
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol (2011) 3.53
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology (2009) 3.30
Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol (2005) 3.29
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med (2007) 3.07
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol (2011) 3.05
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov (2012) 3.04
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med (2003) 3.01
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 3.00
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med (2006) 2.83
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood (2010) 2.73
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol (2008) 2.68
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood (2011) 2.68
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol (2012) 2.59
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol (2011) 2.58
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
Developing a cancer-specific geriatric assessment: a feasibility study. Cancer (2005) 2.57
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol (2008) 2.56
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56